Top-Rated StocksTop-RatedNASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $124.83 -6.12 (-4.67%) Closing price 04:00 PM EasternExtended Trading$124.50 -0.33 (-0.26%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Protagonist Therapeutics Stock (NASDAQ:PTGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PTGX alerts:Sign Up Key Stats Today's Range$124.00▼$131.2850-Day Range$128.75▼$148.1852-Week Range$77.00▼$160.81Volume565,199 shsAverage Volume711,032 shsMarket Capitalization$8.15 billionP/E Ratio26.45Dividend YieldN/APrice Target$166.67Consensus RatingBuy Company Overview Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments. Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V. Patel, Ph.D.AI Generated. May Contain Errors. Read More Protagonist Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScorePTGX MarketRank™: 3.515697443365 of 5 starsProtagonist Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 220th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 1 strong buy rating, 16 buy ratings, no hold ratings, and no sell ratings.Upside PotentialProtagonist Therapeutics has a consensus price target of $166.67, representing about 33.5% upside from its current price of $124.83.Amount of Analyst CoverageProtagonist Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Protagonist Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth-75.91% Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease by -75.91% in the coming year, from $5.52 to $1.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is 26.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is 26.45, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.34.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 12.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.69% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 16.89, which indicates bearish sentiment.Change versus previous monthShort interest in Protagonist Therapeutics has recently decreased by 0.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.97 News SentimentProtagonist Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Protagonist Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,552,987.00 in company stock.Percentage Held by Insiders5.19% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Stock News HeadlinesProtagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to Buy at Wall Street ZenNovember 15 at 10:10 AM | americanbankingnews.comHC Wainwright Has Optimistic Opinion of PTGX FY2026 EarningsNovember 12, 2026 | americanbankingnews.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 16 at 1:00 AM | Behind the Markets (Ad)Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $221.00November 9, 2026 | americanbankingnews.comJ&J posts late-stage trial win for plaque psoriasis pill in psoriatic arthritisNovember 7, 2026 | seekingalpha.comProtagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at Wall Street ZenNovember 7, 2026 | americanbankingnews.comProtagonist Therapeutics (PTGX) Stock Looks Priced At A Premium As Its 7x Three Year Run ContinuesNovember 6, 2026 | finance.yahoo.comProtagonist Therapeutics (PTGX) Swung To Profit, Is It A Bargain Or Fully Priced?November 6, 2026 | finance.yahoo.comSee More Headlines PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $87.34 at the start of the year. Since then, PTGX stock has increased by 42.9% and is now trading at $124.83. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its earnings results on Thursday, November, 5th. The company reported $3.07 EPS for the quarter, beating the consensus estimate of $2.50 by $0.57. The company earned $274.41 million during the quarter, compared to analyst estimates of $238.49 million. Protagonist Therapeutics had a net margin of 62.04% and a trailing twelve-month return on equity of 42.83%. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $90 million in an initial public offering (IPO) on Wednesday, August 10th 2016. The company issued 7,500,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Top institutional investors of Protagonist Therapeutics include State Street Corp (5.33%), Voya Investment Management LLC (0.76%), Pictet Asset Management Holding SA (0.73%) and Stephens Investment Management Group LLC (0.72%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Arturo Md Molina, Harold E Selick, Asif Ali, Bryan Giraudo, William D Waddill and Lewis T Williams. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Palantir Technologies (PLTR), Block (XYZ), Tesla (TSLA) and Viking Therapeutics (VKTX). Company Calendar Last Earnings11/05/2026Today11/16/2026Jefferies Global Healthcare Conference11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (18m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PTGX's financial health is in the Green zone, according to TradeSmith. PTGX has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PTGX CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees141Year Founded2006Price Target and Rating Average Price Target for Protagonist Therapeutics$166.67 High Price Target$221.00 Low Price Target$106.00 Potential Upside/Downside+33.5%Consensus RatingBuy Rating Score (0-4)3.06 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$4.72 Trailing P/E Ratio26.45 Forward P/E Ratio93.86 P/E GrowthN/ANet Income-$130.15 million Net Margins62.04% Pretax Margin63.49% Return on Equity42.83% Return on Assets40.29% Debt Debt-to-Equity RatioN/A Current Ratio19.85 Quick Ratio19.85 Sales & Book Value Annual Sales$46.02 million Price / Sales177.05 Cash FlowN/A Price / Cash FlowN/A Book Value$9.83 per share Price / Book12.70Miscellaneous Outstanding Shares65,270,000Free Float61,882,000Market Cap$8.15 billion OptionableOptionable Beta1.21 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:PTGX) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.